NRG Oncology Lung Cancer Committee Workshop Agenda

Date: Start and End Time: Saturday, July 18th 2:30 – 4:30 pm
Chair: Jeffrey D. Bradley, MD
Co-Chair: Marty Edelman, MD; Gail Darling, MD; Ritsuko Komaki, MD

Learning Objectives:
Following this activity, participants will be better able to:

1. Recognize critical aspects of developing and conducting a clinical trial in Lung (LU) cancer therapy research in a cooperative group setting.
2. Identify and describe the design and status of new LU cancer clinical trials being planned and launched by the RTOG, to enable contribution to protocol design vetting and/or effective patient enrollment in newly-launched studies.
3. Identify and describe the status of ongoing LU cancer clinical trials being conducted by the RTOG, to enable effective patient enrollment in and treatment on these trials, and proper collection, submission and/or evaluation of the required patient data.

WORKSHOP AGENDA

Session I – Active Studies

A. Committee Overview

B. Subcommittee Reports
   a. Thoracic Surgery
   b. Medical Oncology

C. Lung-MAP (SWOG S-1400)

D. ALCHEMIST Trial (Alliance)

E. RTOG 1306/ALLIANCE 31101: EM4-ALK and EGFR Mutant

F. RTOG 1308: Protons vs Photons for St III NSCLC

G. RTOG 0839: Randomized Ph II Pre-Op Chemo/RT ± Panitumumab

H. RTOG 0937: Randomized Phase II PCI plus consolidative RT

I. CALGB 30610/RTOG 0538: Intergroup Phase III

J. RTOG 1106/ACRIN: Adaptive RT in Stage III

K. NRG-LU001: Phase IIIR: ChemoRT ± Metformin

L. RTOG BR-001: Phase I study of SBRT for multiple mets

Session II – Concepts in Development

A. Chemo/RT +/- Nivolumab for Stage III (RTOG Foundation Trial)
   a. Contract development with BMS

B. NRG-CC1432: Hippocampal Avoidance for PCI (Small Cell)

C. 2nd Generation ALK for Stage IV

QUESTIONS / DISCUSSION

Jeffrey Bradley, MD